<![CDATA[Tebentafusp Sustains Survival Benefit at 5 Years in Metastatic Uveal Melanoma ]]>

Data ReadoutpositivetebentafuspPositive

AI Analysis

Summary

Tebentafusp demonstrated sustained overall survival benefit over investigator's choice in a 5-year final analysis of the IMCgp100-202 trial in untreated HLA-A*02:01-positive metastatic uveal melanoma patients.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Final 5-year IMCgp100-202 data show tebentafusp improved overall survival versus investigator's choice in untreated HLA-A*02:01-positive metastatic uveal melanoma

Importance:7/10

Sentiment:

0.80

oncologyuveal melanomasurvival benefitlong-term dataimmunotherapy

Related Companies

$IMCR

Read the original article

Published by Cancer Network on September 22, 2026 6:00 PM

Read Original